Aurobindo Pharma Limited Drug For Further Processing
NDC Database
Aurobindo Pharma Limited Drug For Further Processing
NDC Database
National Drug Code (NDC) records including drug products, NDC numbers, nonproprietary names, dosage forms, strengths, labelers and marketing information.
- Total Records 532
- Latest Marketing Date 2026-01-15
- Data Source FDA
- First Marketing Date 2004-10-22
Company Overview
Company
Aurobindo Pharma Limited Drug For Further Processing
Country
India
Website
Social Profiles
Company Snapshot
Aurobindo Pharma Limited Drug For Further Processing
Plot no. 2, Maitrivihar, Ameerpet, Hyderabad - 500038 Andhra Pradesh
India
www.aurobindo.com/ info@aurobindo.com View on MapNDC Records ( 532 records )
Nonproprietary Name
Omeprazole
Dosage Form
CAPSULE, DELAYED RELEASE
Strength
10 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
OMEPRAZOLE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2015-08-19
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Omeprazole
Dosage Form
CAPSULE, DELAYED RELEASE
Strength
20 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
OMEPRAZOLE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2015-08-19
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Omeprazole
Dosage Form
CAPSULE, DELAYED RELEASE
Strength
40 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
OMEPRAZOLE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2015-08-19
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Ranolazine
Dosage Form
TABLET, FILM COATED, EXTENDED RELEASE
Strength
500 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
RANOLAZINE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2022-12-23
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Ranolazine
Dosage Form
TABLET, FILM COATED, EXTENDED RELEASE
Strength
1000 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
RANOLAZINE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2022-12-23
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Loperamide Hydrochloride
Dosage Form
TABLET
Strength
2 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
LOPERAMIDE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2015-12-15
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Cetirizine Hydrochloride
Dosage Form
CAPSULE
Strength
10 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
CETIRIZINE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2018-07-20
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Cetirizine Hydrochloride
Dosage Form
CAPSULE
Strength
10 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
CETIRIZINE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2018-07-20
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride
Dosage Form
TABLET, FILM COATED, EXTENDED RELEASE
Strength
60; 120 mg/1; mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2017-10-30
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Acetaminophen
Dosage Form
TABLET, EXTENDED RELEASE
Strength
650 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ACETAMINOPHEN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2016-11-09
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Loratadine
Dosage Form
TABLET
Strength
10 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
LORATADINE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2018-04-16
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Esomeprazole Magnesium
Dosage Form
CAPSULE, DELAYED RELEASE
Strength
20 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ESOMEPRAZOLE MAGNESIUM DIHYDRATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2018-03-01
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Omeprazole
Dosage Form
TABLET, DELAYED RELEASE
Strength
20 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
OMEPRAZOLE MAGNESIUM
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2018-06-06
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Famotidine
Dosage Form
TABLET, FILM COATED
Strength
20 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
FAMOTIDINE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2016-04-26
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Guaifenesin and Dextromethorphan HBr
Dosage Form
TABLET, EXTENDED RELEASE
Strength
30; 600 mg/1; mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2017-03-17
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Guaifenesin and Dextromethorphan HBr
Dosage Form
TABLET, EXTENDED RELEASE
Strength
60; 1200 mg/1; mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2017-03-17
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Ibuprofen
Dosage Form
CAPSULE
Strength
200 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
IBUPROFEN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2018-06-29
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Loratadine
Dosage Form
TABLET, ORALLY DISINTEGRATING
Strength
10 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
LORATADINE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2018-04-11
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Ibuprofen
Dosage Form
TABLET
Strength
200 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
IBUPROFEN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2017-11-08
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Ibuprofen
Dosage Form
TABLET
Strength
200 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
IBUPROFEN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2017-11-08
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Cetirizine Hydrochloride
Dosage Form
TABLET
Strength
10 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
CETIRIZINE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2017-02-28
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Cetirizine Hydrochloride
Dosage Form
TABLET
Strength
10 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
CETIRIZINE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2017-02-28
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Guaifenesin
Dosage Form
TABLET, EXTENDED RELEASE
Strength
600 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
GUAIFENESIN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2019-10-21
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Guaifenesin
Dosage Form
TABLET, EXTENDED RELEASE
Strength
1200 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
GUAIFENESIN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2019-10-21
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Famotidine
Dosage Form
TABLET, FILM COATED
Strength
10 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
FAMOTIDINE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2016-04-26
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Diphenhydramine HCl and Ibuprofen
Dosage Form
CAPSULE, LIQUID FILLED
Strength
25; 200 mg/1; mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2019-02-14
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Loperamide Hydrochloride and Simethicone
Dosage Form
TABLET
Strength
125; 2 mg/1; mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
DIMETHICONE; LOPERAMIDE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2020-12-14
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
acetaminophen, aspirin and caffeine
Dosage Form
TABLET, FILM COATED
Strength
250; 250; 65 mg/1; mg/1; mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ACETAMINOPHEN; ASPIRIN; CAFFEINE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2022-02-02
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Loratadine
Dosage Form
CAPSULE
Strength
10 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
LORATADINE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2023-03-24
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Naproxen Sodium
Dosage Form
TABLET, FILM COATED
Strength
220 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
NAPROXEN SODIUM
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2017-12-11
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Glipizide
Dosage Form
TABLET, EXTENDED RELEASE
Strength
2.5 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
GLIPIZIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2017-05-12
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Glipizide
Dosage Form
TABLET, EXTENDED RELEASE
Strength
5 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
GLIPIZIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2017-05-12
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Glipizide
Dosage Form
TABLET, EXTENDED RELEASE
Strength
10 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
GLIPIZIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2017-05-12
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Duloxetine Hydrochloride
Dosage Form
CAPSULE, DELAYED RELEASE
Strength
20 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
DULOXETINE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2019-12-30
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Duloxetine Hydrochloride
Dosage Form
CAPSULE, DELAYED RELEASE
Strength
30 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
DULOXETINE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2019-12-30
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Duloxetine Hydrochloride
Dosage Form
CAPSULE, DELAYED RELEASE
Strength
60 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
DULOXETINE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2019-12-30
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Guaifenesin and Pseudoephedrine HCl
Dosage Form
TABLET, EXTENDED RELEASE
Strength
600; 60 mg/1; mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2020-03-25
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Guaifenesin and Pseudoephedrine HCl
Dosage Form
TABLET, EXTENDED RELEASE
Strength
1200; 120 mg/1; mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2020-03-25
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
ZAFIRLUKAST
Dosage Form
TABLET, FILM COATED
Strength
10 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ZAFIRLUKAST
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2023-11-27
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
ZAFIRLUKAST
Dosage Form
TABLET, FILM COATED
Strength
20 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ZAFIRLUKAST
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2023-11-27
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
CHLORZOXAZONE
Dosage Form
TABLET
Strength
375 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
CHLORZOXAZONE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2023-08-17
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
CHLORZOXAZONE
Dosage Form
TABLET
Strength
500 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
CHLORZOXAZONE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2020-08-03
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
CHLORZOXAZONE
Dosage Form
TABLET
Strength
750 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
CHLORZOXAZONE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2023-08-17
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Fluoxetine
Dosage Form
TABLET, FILM COATED
Strength
10 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
FLUOXETINE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2020-04-08
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Fluoxetine
Dosage Form
TABLET, FILM COATED
Strength
20 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
FLUOXETINE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2020-04-08
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Omeprazole
Dosage Form
CAPSULE, DELAYED RELEASE
Strength
20 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
OMEPRAZOLE MAGNESIUM
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2023-04-28
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Tizanidine Hydrochloride
Dosage Form
CAPSULE
Strength
2 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
TIZANIDINE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2020-03-24
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Tizanidine Hydrochloride
Dosage Form
CAPSULE
Strength
4 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
TIZANIDINE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2020-03-24
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Tizanidine Hydrochloride
Dosage Form
CAPSULE
Strength
6 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
TIZANIDINE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2020-03-24
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Fluoxetine
Dosage Form
TABLET, FILM COATED
Strength
60 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
FLUOXETINE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2020-06-10
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
PHENOXYBENZAMINE HYDROCHLORIDE
Dosage Form
CAPSULE
Strength
10 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
PHENOXYBENZAMINE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2023-05-08
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
FLUCYTOSINE
Dosage Form
CAPSULE
Strength
250 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
FLUCYTOSINE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2020-05-01
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
FLUCYTOSINE
Dosage Form
CAPSULE
Strength
500 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
FLUCYTOSINE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2020-05-01
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Minocycline Hydrochloride
Dosage Form
TABLET, FILM COATED
Strength
50 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
MINOCYCLINE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2020-05-01
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Minocycline Hydrochloride
Dosage Form
TABLET, FILM COATED
Strength
75 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
MINOCYCLINE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2020-05-01
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Minocycline Hydrochloride
Dosage Form
TABLET, FILM COATED
Strength
100 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
MINOCYCLINE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2020-05-01
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
DICLOFENAC POTASSIUM
Dosage Form
CAPSULE, LIQUID FILLED
Strength
25 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
DICLOFENAC POTASSIUM
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2022-03-14
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Ibuprofen
Dosage Form
TABLET
Strength
400 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
IBUPROFEN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2020-05-08
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Ibuprofen
Dosage Form
TABLET
Strength
600 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
IBUPROFEN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2020-05-08
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Ibuprofen
Dosage Form
TABLET
Strength
800 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
IBUPROFEN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2020-05-08
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
ZONISAMIDE
Dosage Form
CAPSULE
Strength
25 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ZONISAMIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2020-08-17
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
ZONISAMIDE
Dosage Form
CAPSULE
Strength
50 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ZONISAMIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2020-08-17
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
ZONISAMIDE
Dosage Form
CAPSULE
Strength
100 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ZONISAMIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2020-08-17
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
CLOMIPRAMINE HYDROCHLORIDE
Dosage Form
CAPSULE
Strength
25 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
CLOMIPRAMINE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2023-03-20
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
CLOMIPRAMINE HYDROCHLORIDE
Dosage Form
CAPSULE
Strength
50 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
CLOMIPRAMINE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2023-03-20
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
CLOMIPRAMINE HYDROCHLORIDE
Dosage Form
CAPSULE
Strength
75 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
CLOMIPRAMINE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2023-03-20
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
BACLOFEN
Dosage Form
TABLET
Strength
10 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
BACLOFEN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2021-07-13
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
BACLOFEN
Dosage Form
TABLET
Strength
20 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
BACLOFEN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2021-07-13
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Ursodiol
Dosage Form
CAPSULE
Strength
300 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
URSODIOL
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2022-11-28
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Cevimeline Hydrochloride
Dosage Form
CAPSULE
Strength
30 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
CEVIMELINE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2023-04-18
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Esomeprazole Magnesium
Dosage Form
TABLET, DELAYED RELEASE
Strength
20 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ESOMEPRAZOLE MAGNESIUM DIHYDRATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2023-07-12
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Tramadol Hydrochloride
Dosage Form
TABLET, FILM COATED
Strength
50 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
TRAMADOL HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
CIV
Start Marketing Date
2020-09-23
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
COLCHICINE
Dosage Form
CAPSULE
Strength
0.6 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
COLCHICINE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2024-04-29
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride
Dosage Form
TABLET, FILM COATED, EXTENDED RELEASE
Strength
180; 240 mg/1; mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2025-04-17
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Colchicine
Dosage Form
TABLET
Strength
0.6 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
COLCHICINE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2022-03-22
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Hydroxyzine Hydrochloride
Dosage Form
TABLET, FILM COATED
Strength
10 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
HYDROXYZINE DIHYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2021-10-07
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Hydroxyzine Hydrochloride
Dosage Form
TABLET, FILM COATED
Strength
25 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
HYDROXYZINE DIHYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2021-10-07
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Hydroxyzine Hydrochloride
Dosage Form
TABLET, FILM COATED
Strength
50 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
HYDROXYZINE DIHYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2021-10-07
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Metformin Hydrochloride
Dosage Form
TABLET, EXTENDED RELEASE
Strength
500 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
METFORMIN HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2024-04-15
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Metformin Hydrochloride
Dosage Form
TABLET, EXTENDED RELEASE
Strength
750 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
METFORMIN HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2024-04-15
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Esomeprazole Magnesium
Dosage Form
CAPSULE, DELAYED RELEASE
Strength
20 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ESOMEPRAZOLE MAGNESIUM
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2023-11-20
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
ESOMEPRAZOLE MAGNESIUM
Dosage Form
CAPSULE, DELAYED RELEASE
Strength
20 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ESOMEPRAZOLE MAGNESIUM TRIHYDRATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2023-11-20
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
ESOMEPRAZOLE MAGNESIUM
Dosage Form
CAPSULE, DELAYED RELEASE
Strength
40 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ESOMEPRAZOLE MAGNESIUM TRIHYDRATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2023-11-20
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
ATORVASTATIN CALCIUM
Dosage Form
TABLET, FILM COATED
Strength
10 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ATORVASTATIN CALCIUM TRIHYDRATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2024-02-13
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
ATORVASTATIN CALCIUM
Dosage Form
TABLET, FILM COATED
Strength
20 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ATORVASTATIN CALCIUM TRIHYDRATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2024-02-13
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
ATORVASTATIN CALCIUM
Dosage Form
TABLET, FILM COATED
Strength
40 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ATORVASTATIN CALCIUM TRIHYDRATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2024-02-13
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
ATORVASTATIN CALCIUM
Dosage Form
TABLET, FILM COATED
Strength
80 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ATORVASTATIN CALCIUM TRIHYDRATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2024-02-13
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Ibuprofen
Dosage Form
CAPSULE
Strength
200 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
IBUPROFEN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2019-04-02
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Cetirizine Hydrochloride
Dosage Form
CAPSULE
Strength
10 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
CETIRIZINE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2021-08-20
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
IBUPROFEN AND PSEUDOEPHEDRINE HCL
Dosage Form
CAPSULE, LIQUID FILLED
Strength
200; 30 mg/1; mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2021-04-27
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Famotidine
Dosage Form
TABLET, FILM COATED
Strength
20 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
FAMOTIDINE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2022-07-15
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Ibuprofen
Dosage Form
TABLET
Strength
200 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
IBUPROFEN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2022-03-22
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Ibuprofen
Dosage Form
TABLET
Strength
200 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
IBUPROFEN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2022-03-22
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
FLUPHENAZINE HYDROCHLORIDE
Dosage Form
TABLET
Strength
1 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
FLUPHENAZINE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2023-08-18
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
FLUPHENAZINE HYDROCHLORIDE
Dosage Form
TABLET
Strength
2.5 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
FLUPHENAZINE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2023-08-18
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
FLUPHENAZINE HYDROCHLORIDE
Dosage Form
TABLET
Strength
5 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
FLUPHENAZINE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2023-08-18
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
FLUPHENAZINE HYDROCHLORIDE
Dosage Form
TABLET
Strength
10 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
FLUPHENAZINE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2023-08-18
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Ibuprofen and Diphenhydramine Citrate
Dosage Form
TABLET, COATED
Strength
38; 200 mg/1; mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
DIPHENHYDRAMINE CITRATE; IBUPROFEN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2022-05-31
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Diphenhydramine HCl and Ibuprofen
Dosage Form
CAPSULE, LIQUID FILLED
Strength
25; 200 mg/1; mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2022-08-10
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
TRAZODONE HYDROCHLORIDE
Dosage Form
TABLET
Strength
50 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
TRAZODONE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2023-02-22
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
TRAZODONE HYDROCHLORIDE
Dosage Form
TABLET
Strength
100 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
TRAZODONE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2023-02-22
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
TRAZODONE HYDROCHLORIDE
Dosage Form
TABLET
Strength
150 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
TRAZODONE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2023-02-22
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
TRAZODONE HYDROCHLORIDE
Dosage Form
TABLET
Strength
300 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
TRAZODONE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2023-02-22
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
CLORAZEPATE DIPOTASSIUM
Dosage Form
TABLET
Strength
3.75 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
CLORAZEPATE DIPOTASSIUM
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
CIV
Start Marketing Date
2023-09-23
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
CLORAZEPATE DIPOTASSIUM
Dosage Form
TABLET
Strength
7.5 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
CLORAZEPATE DIPOTASSIUM
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
CIV
Start Marketing Date
2023-09-23
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
CLORAZEPATE DIPOTASSIUM
Dosage Form
TABLET
Strength
15 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
CLORAZEPATE DIPOTASSIUM
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
CIV
Start Marketing Date
2023-09-23
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
CLONAZEPAM
Dosage Form
TABLET
Strength
0.5 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
CLONAZEPAM
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
CIV
Start Marketing Date
2023-01-17
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
CLONAZEPAM
Dosage Form
TABLET
Strength
1 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
CLONAZEPAM
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
CIV
Start Marketing Date
2023-01-17
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
CLONAZEPAM
Dosage Form
TABLET
Strength
2 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
CLONAZEPAM
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
CIV
Start Marketing Date
2023-01-17
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Cephalexin
Dosage Form
CAPSULE
Strength
750 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
CEPHALEXIN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2023-12-06
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Acetaminophen and Ibuprofen
Dosage Form
TABLET, FILM COATED
Strength
250; 125 mg/1; mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ACETAMINOPHEN; IBUPROFEN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2024-03-26
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
GLYCOPYRROLATE
Dosage Form
TABLET
Strength
1 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
GLYCOPYRROLATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2023-02-28
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
GLYCOPYRROLATE
Dosage Form
TABLET
Strength
2 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
GLYCOPYRROLATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2023-02-28
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Acetaminophen and Ibuprofen
Dosage Form
TABLET, FILM COATED
Strength
250; 125 mg/1; mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ACETAMINOPHEN; IBUPROFEN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2024-03-26
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Glipizide
Dosage Form
TABLET, EXTENDED RELEASE
Strength
2.5 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
GLIPIZIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2023-03-03
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Glipizide
Dosage Form
TABLET, EXTENDED RELEASE
Strength
5 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
GLIPIZIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2023-03-03
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Glipizide
Dosage Form
TABLET, EXTENDED RELEASE
Strength
10 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
GLIPIZIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2023-03-03
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
FUROSEMIDE
Dosage Form
TABLET
Strength
20 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
FUROSEMIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2025-07-17
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
FUROSEMIDE
Dosage Form
TABLET
Strength
40 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
FUROSEMIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2025-07-17
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
FUROSEMIDE
Dosage Form
TABLET
Strength
80 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
FUROSEMIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2025-07-17
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
CIMETIDINE
Dosage Form
TABLET, FILM COATED
Strength
200 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
CIMETIDINE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2024-11-12
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
CIMETIDINE
Dosage Form
TABLET, FILM COATED
Strength
300 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
CIMETIDINE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2024-11-12
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
CIMETIDINE
Dosage Form
TABLET, FILM COATED
Strength
400 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
CIMETIDINE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2024-11-12
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
CIMETIDINE
Dosage Form
TABLET, FILM COATED
Strength
800 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
CIMETIDINE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2024-11-12
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Metformin Hydrochloride
Dosage Form
TABLET, FILM COATED
Strength
500 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
METFORMIN HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2024-03-29
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Metformin Hydrochloride
Dosage Form
TABLET, FILM COATED
Strength
850 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
METFORMIN HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2024-03-29
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Metformin Hydrochloride
Dosage Form
TABLET, FILM COATED
Strength
1000 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
METFORMIN HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2024-03-29
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
POLYETHYLENE GLYCOL 3350
Dosage Form
POWDER, FOR SOLUTION
Strength
17 g/17g
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
POLYETHYLENE GLYCOL 3350
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2024-04-23
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
IBUPROFEN
Dosage Form
CAPSULE, LIQUID FILLED
Strength
200 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
IBUPROFEN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2023-09-14
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Fluoxetine
Dosage Form
CAPSULE
Strength
10 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
FLUOXETINE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2025-07-11
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Fluoxetine
Dosage Form
CAPSULE
Strength
20 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
FLUOXETINE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2025-07-11
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Fluoxetine
Dosage Form
CAPSULE
Strength
40 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
FLUOXETINE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2025-07-11
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Ciprofloxacin Hydrochloride
Dosage Form
TABLET, FILM COATED
Strength
250 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
CIPROFLOXACIN HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2025-03-27
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Ciprofloxacin Hydrochloride
Dosage Form
TABLET, FILM COATED
Strength
500 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
CIPROFLOXACIN HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2025-03-27
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Ciprofloxacin Hydrochloride
Dosage Form
TABLET, FILM COATED
Strength
750 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
CIPROFLOXACIN HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2025-03-27
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
LOPERAMIDE HYDROCHLORIDE
Dosage Form
CAPSULE, LIQUID FILLED
Strength
2 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
LOPERAMIDE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2025-12-29
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Mirtazapine
Dosage Form
TABLET, FILM COATED
Strength
7.5 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
MIRTAZAPINE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2004-10-22
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Mirtazapine
Dosage Form
TABLET, FILM COATED
Strength
30 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
MIRTAZAPINE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2004-10-22
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Citalopram Hydrobromide
Dosage Form
TABLET, FILM COATED
Strength
10 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
CITALOPRAM HYDROBROMIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2004-10-28
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Citalopram Hydrobromide
Dosage Form
TABLET, FILM COATED
Strength
20 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
CITALOPRAM HYDROBROMIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2004-10-28
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Citalopram Hydrobromide
Dosage Form
TABLET, FILM COATED
Strength
40 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
CITALOPRAM HYDROBROMIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2004-10-28
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Metformin Hydrochloride
Dosage Form
TABLET, FILM COATED
Strength
500 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
METFORMIN HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2005-01-14
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Metformin Hydrochloride
Dosage Form
TABLET, FILM COATED
Strength
850 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
METFORMIN HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2005-01-14
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Metformin Hydrochloride
Dosage Form
TABLET, FILM COATED
Strength
1000 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
METFORMIN HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2005-01-14
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Sertraline Hydrochloride
Dosage Form
TABLET, FILM COATED
Strength
25 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
SERTRALINE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2007-02-06
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Sertraline Hydrochloride
Dosage Form
TABLET, FILM COATED
Strength
50 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
SERTRALINE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2007-02-06
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Sertraline Hydrochloride
Dosage Form
TABLET, FILM COATED
Strength
100 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
SERTRALINE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2007-02-06
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Amoxicillin
Dosage Form
TABLET, FILM COATED
Strength
500 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
AMOXICILLIN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2005-11-09
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Amoxicillin
Dosage Form
TABLET, FILM COATED
Strength
875 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
AMOXICILLIN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2005-11-09
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Amoxicillin
Dosage Form
CAPSULE
Strength
250 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
AMOXICILLIN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2005-09-11
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Amoxicillin
Dosage Form
CAPSULE
Strength
500 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
AMOXICILLIN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2005-09-11
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Cephalexin
Dosage Form
CAPSULE
Strength
250 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
CEPHALEXIN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2005-11-16
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Cephalexin
Dosage Form
CAPSULE
Strength
500 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
CEPHALEXIN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2005-11-16
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Mirtazapine
Dosage Form
TABLET, ORALLY DISINTEGRATING
Strength
15 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
MIRTAZAPINE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2005-12-08
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Mirtazapine
Dosage Form
TABLET, ORALLY DISINTEGRATING
Strength
30 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
MIRTAZAPINE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2005-12-08
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Mirtazapine
Dosage Form
TABLET, ORALLY DISINTEGRATING
Strength
45 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
MIRTAZAPINE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2005-12-08
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Zidovudine
Dosage Form
TABLET, FILM COATED
Strength
300 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ZIDOVUDINE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2005-09-19
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Lamivudine
Dosage Form
TABLET, FILM COATED
Strength
150 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
LAMIVUDINE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2016-11-21
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Lamivudine
Dosage Form
TABLET, FILM COATED
Strength
300 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
LAMIVUDINE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2016-11-21
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Nevirapine
Dosage Form
TABLET
Strength
200 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
NEVIRAPINE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2012-05-22
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Mirtazapine
Dosage Form
TABLET, FILM COATED
Strength
15 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
MIRTAZAPINE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2004-10-22
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Mirtazapine
Dosage Form
TABLET, FILM COATED
Strength
45 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
MIRTAZAPINE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2004-10-22
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Lamivudine and Zidovudine
Dosage Form
TABLET, FILM COATED
Strength
150; 300 mg/1; mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
LAMIVUDINE; ZIDOVUDINE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2017-05-05
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Lisinopril
Dosage Form
TABLET
Strength
2.5 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
LISINOPRIL
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2006-02-22
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Lisinopril
Dosage Form
TABLET
Strength
5 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
LISINOPRIL
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2006-02-22
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Lisinopril
Dosage Form
TABLET
Strength
10 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
LISINOPRIL
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2006-02-22
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Lisinopril
Dosage Form
TABLET
Strength
20 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
LISINOPRIL
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2006-02-22
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Lisinopril
Dosage Form
TABLET
Strength
30 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
LISINOPRIL
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2006-02-22
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Lisinopril
Dosage Form
TABLET
Strength
40 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
LISINOPRIL
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2006-02-22
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Lisinopril and Hydrochlorothiazide
Dosage Form
TABLET
Strength
12.5; 10 mg/1; mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
HYDROCHLOROTHIAZIDE; LISINOPRIL
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2006-03-14
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Lisinopril and Hydrochlorothiazide
Dosage Form
TABLET
Strength
12.5; 20 mg/1; mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
HYDROCHLOROTHIAZIDE; LISINOPRIL
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2006-03-14
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Lisinopril and Hydrochlorothiazide
Dosage Form
TABLET
Strength
25; 20 mg/1; mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
HYDROCHLOROTHIAZIDE; LISINOPRIL
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2006-03-14
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Efavirenz
Dosage Form
TABLET, FILM COATED
Strength
600 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
EFAVIRENZ
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2018-09-21
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Simvastatin
Dosage Form
TABLET, FILM COATED
Strength
5 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
SIMVASTATIN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2006-12-20
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Simvastatin
Dosage Form
TABLET, FILM COATED
Strength
10 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
SIMVASTATIN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2006-12-20
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Simvastatin
Dosage Form
TABLET, FILM COATED
Strength
20 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
SIMVASTATIN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2006-12-20
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Simvastatin
Dosage Form
TABLET, FILM COATED
Strength
40 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
SIMVASTATIN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2006-12-20
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Simvastatin
Dosage Form
TABLET, FILM COATED
Strength
80 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
SIMVASTATIN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2006-12-20
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Fluconazole
Dosage Form
TABLET
Strength
50 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
FLUCONAZOLE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2008-10-07
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Fluconazole
Dosage Form
TABLET
Strength
100 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
FLUCONAZOLE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2008-10-07
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Fluconazole
Dosage Form
TABLET
Strength
150 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
FLUCONAZOLE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2008-10-07
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Fluconazole
Dosage Form
TABLET
Strength
200 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
FLUCONAZOLE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2008-10-07
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Metoprolol Tartrate
Dosage Form
TABLET, FILM COATED
Strength
25 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
METOPROLOL TARTRATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2007-09-11
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Metoprolol Tartrate
Dosage Form
TABLET, FILM COATED
Strength
50 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
METOPROLOL TARTRATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2007-09-11
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Metoprolol Tartrate
Dosage Form
TABLET, FILM COATED
Strength
100 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
METOPROLOL TARTRATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2007-09-11
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Cefprozil
Dosage Form
TABLET, FILM COATED
Strength
250 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
CEFPROZIL
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2007-05-24
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Cefprozil
Dosage Form
TABLET, FILM COATED
Strength
500 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
CEFPROZIL
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2007-05-24
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Abacavir
Dosage Form
TABLET, FILM COATED
Strength
300 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ABACAVIR SULFATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2012-12-17
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Terbinafine Hydrochloride
Dosage Form
TABLET
Strength
250 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
TERBINAFINE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2007-07-02
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Glyburide and Metformin Hydrochloride
Dosage Form
TABLET, FILM COATED
Strength
1.25; 250 mg/1; mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
GLYBURIDE; METFORMIN HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2007-11-14
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Glyburide and Metformin Hydrochloride
Dosage Form
TABLET, FILM COATED
Strength
2.5; 500 mg/1; mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
GLYBURIDE; METFORMIN HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2007-11-14
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Glyburide and Metformin Hydrochloride
Dosage Form
TABLET, FILM COATED
Strength
5; 500 mg/1; mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
GLYBURIDE; METFORMIN HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2007-11-14
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Cefadroxil
Dosage Form
CAPSULE
Strength
500 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
CEFADROXIL
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2007-01-25
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Bisoprolol Fumarate
Dosage Form
TABLET, FILM COATED
Strength
5 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
BISOPROLOL FUMARATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2006-12-27
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Bisoprolol Fumarate
Dosage Form
TABLET, FILM COATED
Strength
10 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
BISOPROLOL FUMARATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2006-12-27
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
CEFPODOXIME PROXETIL
Dosage Form
TABLET, FILM COATED
Strength
100 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
CEFPODOXIME PROXETIL
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2007-06-11
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
CEFPODOXIME PROXETIL
Dosage Form
TABLET, FILM COATED
Strength
200 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
CEFPODOXIME PROXETIL
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2007-06-11
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Meloxicam
Dosage Form
TABLET
Strength
7.5 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
MELOXICAM
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2006-10-02
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Meloxicam
Dosage Form
TABLET
Strength
15 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
MELOXICAM
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2006-10-02
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Amlodipine Besylate
Dosage Form
TABLET
Strength
2.5 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
AMLODIPINE BESYLATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2007-07-17
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Amlodipine Besylate
Dosage Form
TABLET
Strength
5 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
AMLODIPINE BESYLATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2007-07-17
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Amlodipine Besylate
Dosage Form
TABLET
Strength
10 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
AMLODIPINE BESYLATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2007-07-17
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Efavirenz
Dosage Form
CAPSULE
Strength
50 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
EFAVIRENZ
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2017-12-15
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Efavirenz
Dosage Form
CAPSULE
Strength
100 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
EFAVIRENZ
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2017-12-15
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Efavirenz
Dosage Form
CAPSULE
Strength
200 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
EFAVIRENZ
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2017-12-15
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Zidovudine
Dosage Form
CAPSULE
Strength
100 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ZIDOVUDINE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2006-03-27
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Hydrochlorothiazide
Dosage Form
CAPSULE
Strength
12.5 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
HYDROCHLOROTHIAZIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2007-09-19
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Benazepril Hydrochloride
Dosage Form
TABLET, FILM COATED
Strength
20 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
BENAZEPRIL HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2008-05-22
End Marketing Date
2026-11-30
Listing Record Certified Through
-
Nonproprietary Name
Benazepril Hydrochloride
Dosage Form
TABLET, FILM COATED
Strength
40 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
BENAZEPRIL HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2008-05-22
End Marketing Date
2026-11-30
Listing Record Certified Through
-
Nonproprietary Name
Torsemide
Dosage Form
TABLET
Strength
5 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
TORSEMIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2007-10-17
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Torsemide
Dosage Form
TABLET
Strength
10 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
TORSEMIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2007-10-17
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Torsemide
Dosage Form
TABLET
Strength
20 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
TORSEMIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2007-10-17
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Torsemide
Dosage Form
TABLET
Strength
100 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
TORSEMIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2007-10-17
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Hydrochlorothiazide
Dosage Form
TABLET
Strength
25 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
HYDROCHLOROTHIAZIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2007-07-20
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Hydrochlorothiazide
Dosage Form
TABLET
Strength
50 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
HYDROCHLOROTHIAZIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2007-07-20
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Carvedilol
Dosage Form
TABLET, FILM COATED
Strength
3.125 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
CARVEDILOL
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2007-09-05
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Carvedilol
Dosage Form
TABLET, FILM COATED
Strength
6.25 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
CARVEDILOL
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2007-09-05
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Carvedilol
Dosage Form
TABLET, FILM COATED
Strength
12.5 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
CARVEDILOL
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2007-09-05
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Carvedilol
Dosage Form
TABLET, FILM COATED
Strength
25 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
CARVEDILOL
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2007-09-05
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Sumatriptan Succinate
Dosage Form
TABLET
Strength
25 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
SUMATRIPTAN SUCCINATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2009-08-17
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Sumatriptan Succinate
Dosage Form
TABLET
Strength
50 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
SUMATRIPTAN SUCCINATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2009-08-17
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Sumatriptan Succinate
Dosage Form
TABLET
Strength
100 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
SUMATRIPTAN SUCCINATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2009-08-17
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Finasteride
Dosage Form
TABLET, FILM COATED
Strength
5 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
FINASTERIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2007-10-30
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Paroxetine Hydrochloride
Dosage Form
TABLET, FILM COATED
Strength
10 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
PAROXETINE HYDROCHLORIDE HEMIHYDRATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2007-07-25
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Paroxetine Hydrochloride
Dosage Form
TABLET, FILM COATED
Strength
20 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
PAROXETINE HYDROCHLORIDE HEMIHYDRATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2007-07-25
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Paroxetine Hydrochloride
Dosage Form
TABLET, FILM COATED
Strength
30 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
PAROXETINE HYDROCHLORIDE HEMIHYDRATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2007-07-25
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Paroxetine Hydrochloride
Dosage Form
TABLET, FILM COATED
Strength
40 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
PAROXETINE HYDROCHLORIDE HEMIHYDRATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2007-07-25
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
carisoprodol
Dosage Form
TABLET
Strength
350 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
CARISOPRODOL
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
CIV
Start Marketing Date
2009-08-06
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Zolpidem Tartrate
Dosage Form
TABLET, FILM COATED
Strength
5 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ZOLPIDEM TARTRATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
CIV
Start Marketing Date
2007-05-04
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Zolpidem Tartrate
Dosage Form
TABLET, FILM COATED
Strength
10 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ZOLPIDEM TARTRATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
CIV
Start Marketing Date
2007-05-04
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Quinapril Hydrochloride/Hydrochlorothiazide
Dosage Form
TABLET, FILM COATED
Strength
12.5; 10 mg/1; mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2007-08-24
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Quinapril Hydrochloride/Hydrochlorothiazide
Dosage Form
TABLET, FILM COATED
Strength
12.5; 20 mg/1; mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2007-08-24
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Quinapril Hydrochloride/Hydrochlorothiazide
Dosage Form
TABLET, FILM COATED
Strength
25; 20 mg/1; mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2007-08-24
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Trandolapril
Dosage Form
TABLET
Strength
1 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
TRANDOLAPRIL
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2007-06-12
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Trandolapril
Dosage Form
TABLET
Strength
2 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
TRANDOLAPRIL
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2007-06-12
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Trandolapril
Dosage Form
TABLET
Strength
4 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
TRANDOLAPRIL
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2007-06-12
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Atenolol
Dosage Form
TABLET
Strength
25 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ATENOLOL
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2007-10-31
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Atenolol
Dosage Form
TABLET
Strength
50 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ATENOLOL
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2007-10-31
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Atenolol
Dosage Form
TABLET
Strength
100 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ATENOLOL
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2007-10-31
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Topiramate
Dosage Form
TABLET, FILM COATED
Strength
25 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
TOPIRAMATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2009-03-27
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Topiramate
Dosage Form
TABLET, FILM COATED
Strength
50 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
TOPIRAMATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2009-03-27
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Topiramate
Dosage Form
TABLET, FILM COATED
Strength
100 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
TOPIRAMATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2009-03-27
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Topiramate
Dosage Form
TABLET, FILM COATED
Strength
200 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
TOPIRAMATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2009-03-27
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Penicillin V Potassium
Dosage Form
TABLET, FILM COATED
Strength
250 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
PENICILLIN V POTASSIUM
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2008-04-29
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Penicillin V Potassium
Dosage Form
TABLET, FILM COATED
Strength
500 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
PENICILLIN V POTASSIUM
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2008-04-29
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
cefdinir
Dosage Form
CAPSULE
Strength
300 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
CEFDINIR
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2008-01-07
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Clindamycin Hydrochloride
Dosage Form
CAPSULE
Strength
150 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
CLINDAMYCIN HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2009-08-26
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Clindamycin Hydrochloride
Dosage Form
CAPSULE
Strength
300 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
CLINDAMYCIN HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2009-08-26
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Ondansetron Hydrochloride
Dosage Form
TABLET, FILM COATED
Strength
4 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ONDANSETRON HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2007-07-31
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Ondansetron Hydrochloride
Dosage Form
TABLET, FILM COATED
Strength
8 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ONDANSETRON HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2007-07-31
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Ondansetron Hydrochloride
Dosage Form
TABLET, FILM COATED
Strength
24 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ONDANSETRON HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2007-07-31
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Cyclobenzaprine Hydrochloride
Dosage Form
TABLET, FILM COATED
Strength
5 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
CYCLOBENZAPRINE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2008-09-26
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Cyclobenzaprine Hydrochloride
Dosage Form
TABLET, FILM COATED
Strength
10 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
CYCLOBENZAPRINE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2008-09-26
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Fluoxetine Hydrochloride
Dosage Form
CAPSULE
Strength
10 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
FLUOXETINE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2008-01-31
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Fluoxetine Hydrochloride
Dosage Form
CAPSULE
Strength
20 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
FLUOXETINE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2008-01-31
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Fluoxetine Hydrochloride
Dosage Form
CAPSULE
Strength
40 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
FLUOXETINE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2008-01-31
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Gabapentin
Dosage Form
CAPSULE
Strength
100 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
GABAPENTIN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2008-01-31
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Gabapentin
Dosage Form
CAPSULE
Strength
300 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
GABAPENTIN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2008-01-31
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Gabapentin
Dosage Form
CAPSULE
Strength
400 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
GABAPENTIN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2008-01-31
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Losartan Potassium
Dosage Form
TABLET, FILM COATED
Strength
25 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
LOSARTAN POTASSIUM
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2010-10-06
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Losartan Potassium
Dosage Form
TABLET, FILM COATED
Strength
50 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
LOSARTAN POTASSIUM
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2010-10-06
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Losartan Potassium
Dosage Form
TABLET, FILM COATED
Strength
100 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
LOSARTAN POTASSIUM
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2010-10-06
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Ribavirin
Dosage Form
TABLET, FILM COATED
Strength
200 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
RIBAVIRIN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2009-09-17
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Minocycline Hydrochloride
Dosage Form
CAPSULE
Strength
50 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
MINOCYCLINE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2008-03-11
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Minocycline Hydrochloride
Dosage Form
CAPSULE
Strength
75 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
MINOCYCLINE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2008-03-11
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Minocycline Hydrochloride
Dosage Form
CAPSULE
Strength
100 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
MINOCYCLINE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2008-03-11
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
ZALEPLON
Dosage Form
CAPSULE
Strength
5 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ZALEPLON
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
CIV
Start Marketing Date
2008-06-06
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
ZALEPLON
Dosage Form
CAPSULE
Strength
10 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ZALEPLON
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
CIV
Start Marketing Date
2008-06-06
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Clarithromycin
Dosage Form
TABLET, FILM COATED
Strength
250 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
CLARITHROMYCIN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2012-07-25
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Clarithromycin
Dosage Form
TABLET, FILM COATED
Strength
500 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
CLARITHROMYCIN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2012-07-25
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Lamotrigine
Dosage Form
TABLET
Strength
25 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
LAMOTRIGINE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2009-01-27
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Lamotrigine
Dosage Form
TABLET
Strength
100 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
LAMOTRIGINE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2009-01-27
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Lamotrigine
Dosage Form
TABLET
Strength
150 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
LAMOTRIGINE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2009-01-27
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Lamotrigine
Dosage Form
TABLET
Strength
200 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
LAMOTRIGINE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2009-01-27
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Ibandronate Sodium
Dosage Form
TABLET, FILM COATED
Strength
150 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
IBANDRONATE SODIUM
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2016-03-11
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Atomoxetine
Dosage Form
CAPSULE
Strength
10 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ATOMOXETINE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2017-05-30
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Atomoxetine
Dosage Form
CAPSULE
Strength
18 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ATOMOXETINE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2017-05-30
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Atomoxetine
Dosage Form
CAPSULE
Strength
25 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ATOMOXETINE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2017-05-30
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Atomoxetine
Dosage Form
CAPSULE
Strength
40 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ATOMOXETINE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2017-05-30
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Atomoxetine
Dosage Form
CAPSULE
Strength
60 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ATOMOXETINE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2017-05-30
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Atomoxetine
Dosage Form
CAPSULE
Strength
80 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ATOMOXETINE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2017-05-30
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Atomoxetine
Dosage Form
CAPSULE
Strength
100 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ATOMOXETINE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2017-05-30
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Levetiracetam
Dosage Form
TABLET, FILM COATED
Strength
250 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
LEVETIRACETAM
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2009-01-15
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Levetiracetam
Dosage Form
TABLET, FILM COATED
Strength
500 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
LEVETIRACETAM
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2009-01-15
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Levetiracetam
Dosage Form
TABLET, FILM COATED
Strength
750 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
LEVETIRACETAM
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2009-01-15
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Alfuzosin Hydrochloride
Dosage Form
TABLET, FILM COATED, EXTENDED RELEASE
Strength
10 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ALFUZOSIN HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2012-08-30
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Perindopril Erbumine
Dosage Form
TABLET
Strength
2 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
PERINDOPRIL ERBUMINE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2009-11-10
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Perindopril Erbumine
Dosage Form
TABLET
Strength
4 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
PERINDOPRIL ERBUMINE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2009-11-10
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Perindopril Erbumine
Dosage Form
TABLET
Strength
8 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
PERINDOPRIL ERBUMINE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2009-11-10
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Ribavirin
Dosage Form
CAPSULE
Strength
200 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
RIBAVIRIN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2009-09-17
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Rosuvastatin Calcium
Dosage Form
TABLET, FILM COATED
Strength
5 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ROSUVASTATIN CALCIUM
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2016-07-19
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Rosuvastatin Calcium
Dosage Form
TABLET, FILM COATED
Strength
10 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ROSUVASTATIN CALCIUM
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2016-07-19
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Rosuvastatin Calcium
Dosage Form
TABLET, FILM COATED
Strength
20 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ROSUVASTATIN CALCIUM
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2016-07-19
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Rosuvastatin Calcium
Dosage Form
TABLET, FILM COATED
Strength
40 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ROSUVASTATIN CALCIUM
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2016-07-19
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Emtricitabine
Dosage Form
CAPSULE
Strength
200 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
EMTRICITABINE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2023-03-15
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Fosinopril Sodium and Hydrochlorothiazide
Dosage Form
TABLET
Strength
10; 12.5 mg/1; mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2009-07-09
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Fosinopril Sodium and Hydrochlorothiazide
Dosage Form
TABLET
Strength
20; 12.5 mg/1; mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2009-07-09
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Levetiracetam
Dosage Form
TABLET, FILM COATED
Strength
1000 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
LEVETIRACETAM
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2009-01-15
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Donepezil Hydrochloride
Dosage Form
TABLET, FILM COATED
Strength
5 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
DONEPEZIL HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2011-05-31
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Donepezil Hydrochloride
Dosage Form
TABLET, FILM COATED
Strength
10 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
DONEPEZIL HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2011-05-31
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Alendronate Sodium
Dosage Form
TABLET
Strength
10 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ALENDRONATE SODIUM
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2008-08-04
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Alendronate Sodium
Dosage Form
TABLET
Strength
35 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ALENDRONATE SODIUM
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2008-08-04
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Alendronate Sodium
Dosage Form
TABLET
Strength
70 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ALENDRONATE SODIUM
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2008-08-04
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
abacavir and lamivudine
Dosage Form
TABLET, FILM COATED
Strength
600; 300 mg/1; mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ABACAVIR SULFATE; LAMIVUDINE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2018-11-15
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Emtricitabine and Tenofovir Disoproxil Fumarate
Dosage Form
TABLET, FILM COATED
Strength
200; 300 mg/1; mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2021-03-30
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Clopidogrel Bisulfate
Dosage Form
TABLET, FILM COATED
Strength
75 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
CLOPIDOGREL BISULFATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2012-05-17
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Sulfamethoxazole and Trimethoprim
Dosage Form
TABLET
Strength
400; 80 mg/1; mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
SULFAMETHOXAZOLE; TRIMETHOPRIM
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2010-02-16
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Sulfamethoxazole and Trimethoprim
Dosage Form
TABLET
Strength
800; 160 mg/1; mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
SULFAMETHOXAZOLE; TRIMETHOPRIM
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2010-02-16
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Tenofovir Disoproxil Fumarate
Dosage Form
TABLET, FILM COATED
Strength
300 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
TENOFOVIR DISOPROXIL FUMARATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2018-01-26
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Cetirizine Hydrochloride
Dosage Form
TABLET
Strength
5 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
CETIRIZINE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2015-08-05
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Cetirizine Hydrochloride
Dosage Form
TABLET
Strength
10 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
CETIRIZINE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2015-08-05
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Cetirizine Hydrochloride
Dosage Form
TABLET
Strength
5 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
CETIRIZINE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2015-08-05
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Cetirizine Hydrochloride
Dosage Form
TABLET
Strength
10 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
CETIRIZINE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2015-08-05
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Alprazolam
Dosage Form
TABLET, EXTENDED RELEASE
Strength
0.5 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ALPRAZOLAM
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
CIV
Start Marketing Date
2011-06-07
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Alprazolam
Dosage Form
TABLET, EXTENDED RELEASE
Strength
1 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ALPRAZOLAM
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
CIV
Start Marketing Date
2011-06-07
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Alprazolam
Dosage Form
TABLET, EXTENDED RELEASE
Strength
2 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ALPRAZOLAM
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
CIV
Start Marketing Date
2011-06-07
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Alprazolam
Dosage Form
TABLET, EXTENDED RELEASE
Strength
3 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ALPRAZOLAM
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
CIV
Start Marketing Date
2011-06-07
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Galantamine
Dosage Form
TABLET, FILM COATED
Strength
4 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
GALANTAMINE HYDROBROMIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2011-03-29
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Galantamine
Dosage Form
TABLET, FILM COATED
Strength
8 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
GALANTAMINE HYDROBROMIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2011-03-29
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Galantamine
Dosage Form
TABLET, FILM COATED
Strength
12 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
GALANTAMINE HYDROBROMIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2011-03-29
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Famciclovir
Dosage Form
TABLET, FILM COATED
Strength
125 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
FAMCICLOVIR
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2011-03-21
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Famciclovir
Dosage Form
TABLET, FILM COATED
Strength
250 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
FAMCICLOVIR
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2011-03-21
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Famciclovir
Dosage Form
TABLET, FILM COATED
Strength
500 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
FAMCICLOVIR
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2011-03-21
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Losartan Potassium and Hydrochlorothiazide
Dosage Form
TABLET, FILM COATED
Strength
12.5; 50 mg/1; mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2010-10-06
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Losartan Potassium and Hydrochlorothiazide
Dosage Form
TABLET, FILM COATED
Strength
12.5; 100 mg/1; mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2010-10-06
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Losartan Potassium and Hydrochlorothiazide
Dosage Form
TABLET, FILM COATED
Strength
25; 100 mg/1; mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2010-10-06
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Fosinopril Sodium
Dosage Form
TABLET
Strength
10 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
FOSINOPRIL SODIUM
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2011-03-30
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Fosinopril Sodium
Dosage Form
TABLET
Strength
20 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
FOSINOPRIL SODIUM
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2011-03-30
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Fosinopril Sodium
Dosage Form
TABLET
Strength
40 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
FOSINOPRIL SODIUM
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2011-03-30
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Ramipril
Dosage Form
CAPSULE
Strength
1.25 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
RAMIPRIL
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2011-06-08
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Ramipril
Dosage Form
CAPSULE
Strength
2.5 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
RAMIPRIL
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2011-06-08
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Ramipril
Dosage Form
CAPSULE
Strength
5 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
RAMIPRIL
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2011-06-08
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Ramipril
Dosage Form
CAPSULE
Strength
10 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
RAMIPRIL
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2011-06-08
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Quetiapine Fumarate
Dosage Form
TABLET, FILM COATED
Strength
25 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
QUETIAPINE FUMARATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2012-03-27
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Quetiapine Fumarate
Dosage Form
TABLET, FILM COATED
Strength
50 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
QUETIAPINE FUMARATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2012-03-27
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Quetiapine Fumarate
Dosage Form
TABLET, FILM COATED
Strength
100 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
QUETIAPINE FUMARATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2012-03-27
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Quetiapine Fumarate
Dosage Form
TABLET, FILM COATED
Strength
150 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
QUETIAPINE FUMARATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2012-03-27
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Quetiapine Fumarate
Dosage Form
TABLET, FILM COATED
Strength
200 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
QUETIAPINE FUMARATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2012-03-27
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Quetiapine Fumarate
Dosage Form
TABLET, FILM COATED
Strength
300 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
QUETIAPINE FUMARATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2012-03-27
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Quetiapine Fumarate
Dosage Form
TABLET, FILM COATED
Strength
400 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
QUETIAPINE FUMARATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2012-03-27
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
EFAVIRENZ, EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE
Dosage Form
TABLET, FILM COATED
Strength
600; 200; 300 mg/1; mg/1; mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2021-03-30
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Amoxicillin and Clavulanate Potassium
Dosage Form
TABLET, FILM COATED
Strength
250; 125 mg/1; mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
AMOXICILLIN; CLAVULANATE POTASSIUM
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2012-01-20
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Amoxicillin and Clavulanate Potassium
Dosage Form
TABLET, FILM COATED
Strength
500; 125 mg/1; mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
AMOXICILLIN; CLAVULANATE POTASSIUM
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2012-01-20
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Amoxicillin and Clavulanate Potassium
Dosage Form
TABLET, FILM COATED
Strength
875; 125 mg/1; mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
AMOXICILLIN; CLAVULANATE POTASSIUM
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2012-01-20
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Pioglitazone Hydrochloride
Dosage Form
TABLET
Strength
15 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
PIOGLITAZONE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2013-02-13
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Pioglitazone Hydrochloride
Dosage Form
TABLET
Strength
30 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
PIOGLITAZONE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2013-02-13
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Pioglitazone Hydrochloride
Dosage Form
TABLET
Strength
45 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
PIOGLITAZONE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2013-02-13
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Naproxen Sodium
Dosage Form
TABLET, FILM COATED
Strength
275 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
NAPROXEN SODIUM
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2011-10-31
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Naproxen Sodium
Dosage Form
TABLET, FILM COATED
Strength
550 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
NAPROXEN SODIUM
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2011-10-31
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Risedronate Sodium
Dosage Form
TABLET, FILM COATED
Strength
5 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
RISEDRONATE SODIUM
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2015-11-30
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Risedronate Sodium
Dosage Form
TABLET, FILM COATED
Strength
30 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
RISEDRONATE SODIUM
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2015-11-30
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Risedronate Sodium
Dosage Form
TABLET, FILM COATED
Strength
35 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
RISEDRONATE SODIUM
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2015-11-30
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Naproxen
Dosage Form
TABLET
Strength
250 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
NAPROXEN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2011-11-08
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Naproxen
Dosage Form
TABLET
Strength
375 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
NAPROXEN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2011-11-08
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Naproxen
Dosage Form
TABLET
Strength
500 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
NAPROXEN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2011-11-08
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Gabapentin
Dosage Form
TABLET, FILM COATED
Strength
600 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
GABAPENTIN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2011-10-06
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Gabapentin
Dosage Form
TABLET, FILM COATED
Strength
800 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
GABAPENTIN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2011-10-06
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Pioglitazone Hydrochloride and Metformin Hydrochloride
Dosage Form
TABLET, FILM COATED
Strength
500; 15 mg/1; mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2013-02-13
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Pioglitazone Hydrochloride and Metformin Hydrochloride
Dosage Form
TABLET, FILM COATED
Strength
850; 15 mg/1; mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2013-02-13
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Venlafaxine Hydrochloride
Dosage Form
CAPSULE, EXTENDED RELEASE
Strength
37.5 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
VENLAFAXINE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2011-06-01
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Venlafaxine Hydrochloride
Dosage Form
CAPSULE, EXTENDED RELEASE
Strength
75 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
VENLAFAXINE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2011-06-01
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Levofloxacin
Dosage Form
TABLET, FILM COATED
Strength
250 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
LEVOFLOXACIN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2011-06-20
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Levofloxacin
Dosage Form
TABLET, FILM COATED
Strength
500 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
LEVOFLOXACIN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2011-06-20
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Levofloxacin
Dosage Form
TABLET, FILM COATED
Strength
750 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
LEVOFLOXACIN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2011-06-20
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Valsartan and Hydrochlorothiazide
Dosage Form
TABLET, FILM COATED
Strength
12.5; 80 mg/1; mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
HYDROCHLOROTHIAZIDE; VALSARTAN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2013-03-21
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Valsartan and Hydrochlorothiazide
Dosage Form
TABLET, FILM COATED
Strength
12.5; 160 mg/1; mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
HYDROCHLOROTHIAZIDE; VALSARTAN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2013-03-21
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Valsartan and Hydrochlorothiazide
Dosage Form
TABLET, FILM COATED
Strength
25; 160 mg/1; mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
HYDROCHLOROTHIAZIDE; VALSARTAN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2013-03-21
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Valsartan and Hydrochlorothiazide
Dosage Form
TABLET, FILM COATED
Strength
12.5; 320 mg/1; mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
HYDROCHLOROTHIAZIDE; VALSARTAN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2013-03-21
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Valsartan and Hydrochlorothiazide
Dosage Form
TABLET, FILM COATED
Strength
25; 320 mg/1; mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
HYDROCHLOROTHIAZIDE; VALSARTAN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2013-03-21
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Minocycline Hydrochloride
Dosage Form
TABLET, FILM COATED, EXTENDED RELEASE
Strength
45 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
MINOCYCLINE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2012-11-19
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Minocycline Hydrochloride
Dosage Form
TABLET, FILM COATED, EXTENDED RELEASE
Strength
65 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
MINOCYCLINE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2018-09-28
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Minocycline Hydrochloride
Dosage Form
TABLET, FILM COATED, EXTENDED RELEASE
Strength
90 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
MINOCYCLINE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2012-11-19
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Minocycline Hydrochloride
Dosage Form
TABLET, FILM COATED, EXTENDED RELEASE
Strength
115 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
MINOCYCLINE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2018-09-28
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Minocycline Hydrochloride
Dosage Form
TABLET, FILM COATED, EXTENDED RELEASE
Strength
135 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
MINOCYCLINE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2012-11-19
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Pantoprazole Sodium
Dosage Form
TABLET, DELAYED RELEASE
Strength
20 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
PANTOPRAZOLE SODIUM
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2012-09-28
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Pantoprazole Sodium
Dosage Form
TABLET, DELAYED RELEASE
Strength
40 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
PANTOPRAZOLE SODIUM
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2012-09-28
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Olanzapine
Dosage Form
TABLET
Strength
2.5 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
OLANZAPINE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2012-04-23
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Olanzapine
Dosage Form
TABLET
Strength
5 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
OLANZAPINE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2012-04-23
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Olanzapine
Dosage Form
TABLET
Strength
7.5 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
OLANZAPINE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2012-04-23
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Olanzapine
Dosage Form
TABLET
Strength
10 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
OLANZAPINE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2012-04-23
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Olanzapine
Dosage Form
TABLET
Strength
15 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
OLANZAPINE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2012-04-23
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Olanzapine
Dosage Form
TABLET
Strength
20 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
OLANZAPINE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2012-04-23
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Montelukast Sodium
Dosage Form
TABLET, CHEWABLE
Strength
4 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
MONTELUKAST SODIUM
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2012-08-03
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Montelukast Sodium
Dosage Form
TABLET, CHEWABLE
Strength
5 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
MONTELUKAST SODIUM
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2012-08-03
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Valsartan
Dosage Form
TABLET, FILM COATED
Strength
40 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
VALSARTAN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2015-01-05
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Valsartan
Dosage Form
TABLET, FILM COATED
Strength
80 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
VALSARTAN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2015-01-05
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Valsartan
Dosage Form
TABLET, FILM COATED
Strength
160 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
VALSARTAN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2015-01-05
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Valsartan
Dosage Form
TABLET, FILM COATED
Strength
320 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
VALSARTAN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2015-01-05
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Montelukast Sodium
Dosage Form
TABLET, FILM COATED
Strength
10 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
MONTELUKAST SODIUM
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2012-08-03
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Glimepiride
Dosage Form
TABLET
Strength
1 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
GLIMEPIRIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2012-06-29
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Glimepiride
Dosage Form
TABLET
Strength
2 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
GLIMEPIRIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2012-06-29
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Glimepiride
Dosage Form
TABLET
Strength
4 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
GLIMEPIRIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2012-06-29
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Amlodipine and Benazepril Hydrochloride
Dosage Form
CAPSULE
Strength
2.5; 10 mg/1; mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2012-09-05
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Amlodipine and Benazepril Hydrochloride
Dosage Form
CAPSULE
Strength
5; 10 mg/1; mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2012-09-05
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Amlodipine and Benazepril Hydrochloride
Dosage Form
CAPSULE
Strength
5; 20 mg/1; mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2012-09-05
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Amlodipine and Benazepril Hydrochloride
Dosage Form
CAPSULE
Strength
5; 40 mg/1; mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2012-09-05
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Amlodipine and Benazepril Hydrochloride
Dosage Form
CAPSULE
Strength
10; 20 mg/1; mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2012-09-05
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Amlodipine and Benazepril Hydrochloride
Dosage Form
CAPSULE
Strength
10; 40 mg/1; mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2012-09-05
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Divalproex sodium
Dosage Form
TABLET, FILM COATED, EXTENDED RELEASE
Strength
250 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
DIVALPROEX SODIUM
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2014-06-02
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Divalproex sodium
Dosage Form
TABLET, FILM COATED, EXTENDED RELEASE
Strength
500 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
DIVALPROEX SODIUM
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2014-06-02
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Tamsulosin Hydrochloride
Dosage Form
CAPSULE
Strength
0.4 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
TAMSULOSIN HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2013-04-30
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Rizatriptan Benzoate
Dosage Form
TABLET
Strength
5 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
RIZATRIPTAN BENZOATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2012-12-31
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Rizatriptan Benzoate
Dosage Form
TABLET
Strength
10 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
RIZATRIPTAN BENZOATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2012-12-31
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Modafinil
Dosage Form
TABLET
Strength
100 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
MODAFINIL
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
CIV
Start Marketing Date
2012-09-27
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Modafinil
Dosage Form
TABLET
Strength
200 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
MODAFINIL
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
CIV
Start Marketing Date
2012-09-27
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Moxifloxacin Hydrochloride
Dosage Form
TABLET, FILM COATED
Strength
400 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
MOXIFLOXACIN HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2014-03-04
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Pramipexole Dihydrochloride
Dosage Form
TABLET
Strength
0.125 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
PRAMIPEXOLE DIHYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2012-10-26
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Pramipexole Dihydrochloride
Dosage Form
TABLET
Strength
0.25 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
PRAMIPEXOLE DIHYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2012-10-26
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Pramipexole Dihydrochloride
Dosage Form
TABLET
Strength
0.5 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
PRAMIPEXOLE DIHYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2012-10-26
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Pramipexole Dihydrochloride
Dosage Form
TABLET
Strength
0.75 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
PRAMIPEXOLE DIHYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2012-10-26
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Pramipexole Dihydrochloride
Dosage Form
TABLET
Strength
1 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
PRAMIPEXOLE DIHYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2012-10-26
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Pramipexole Dihydrochloride
Dosage Form
TABLET
Strength
1.5 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
PRAMIPEXOLE DIHYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2012-10-26
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Quinapril Hydrochloride
Dosage Form
TABLET, FILM COATED
Strength
5 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
QUINAPRIL HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2013-04-29
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Quinapril Hydrochloride
Dosage Form
TABLET, FILM COATED
Strength
10 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
QUINAPRIL HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2013-04-29
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Quinapril Hydrochloride
Dosage Form
TABLET, FILM COATED
Strength
20 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
QUINAPRIL HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2013-04-29
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Quinapril Hydrochloride
Dosage Form
TABLET, FILM COATED
Strength
40 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
QUINAPRIL HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2013-04-29
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Flecainide Acetate
Dosage Form
TABLET
Strength
50 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
FLECAINIDE ACETATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2015-07-08
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Flecainide Acetate
Dosage Form
TABLET
Strength
100 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
FLECAINIDE ACETATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2015-07-08
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Flecainide Acetate
Dosage Form
TABLET
Strength
150 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
FLECAINIDE ACETATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2015-07-08
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Gemfibrozil
Dosage Form
TABLET, FILM COATED
Strength
600 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
GEMFIBROZIL
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2015-09-16
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Rizatriptan Benzoate
Dosage Form
TABLET, ORALLY DISINTEGRATING
Strength
5 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
RIZATRIPTAN BENZOATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2013-07-01
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Rizatriptan Benzoate
Dosage Form
TABLET, ORALLY DISINTEGRATING
Strength
10 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
RIZATRIPTAN BENZOATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2013-07-01
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Irbesartan and Hydrochlorothiazide
Dosage Form
TABLET, FILM COATED
Strength
12.5; 150 mg/1; mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
HYDROCHLOROTHIAZIDE; IRBESARTAN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2013-02-22
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Irbesartan and Hydrochlorothiazide
Dosage Form
TABLET, FILM COATED
Strength
12.5; 300 mg/1; mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
HYDROCHLOROTHIAZIDE; IRBESARTAN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2013-02-22
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Irbesartan and Hydrochlorothiazide
Dosage Form
TABLET, FILM COATED
Strength
25; 300 mg/1; mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
HYDROCHLOROTHIAZIDE; IRBESARTAN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2016-03-31
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Pravastatin sodium
Dosage Form
TABLET
Strength
10 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
PRAVASTATIN SODIUM
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2017-02-02
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Pravastatin sodium
Dosage Form
TABLET
Strength
20 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
PRAVASTATIN SODIUM
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2017-02-02
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Pravastatin sodium
Dosage Form
TABLET
Strength
40 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
PRAVASTATIN SODIUM
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2017-02-02
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Pravastatin sodium
Dosage Form
TABLET
Strength
80 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
PRAVASTATIN SODIUM
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2017-02-02
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Irbesartan
Dosage Form
TABLET
Strength
75 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
IRBESARTAN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2012-09-27
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Irbesartan
Dosage Form
TABLET
Strength
150 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
IRBESARTAN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2012-09-27
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Irbesartan
Dosage Form
TABLET
Strength
300 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
IRBESARTAN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2012-09-27
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
azithromycin
Dosage Form
TABLET, FILM COATED
Strength
250 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
AZITHROMYCIN DIHYDRATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2020-09-16
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
azithromycin
Dosage Form
TABLET, FILM COATED
Strength
500 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
AZITHROMYCIN DIHYDRATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2020-09-16
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Rivastigmine Tartrate
Dosage Form
CAPSULE
Strength
1.5 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
RIVASTIGMINE TARTRATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2016-03-25
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Rivastigmine Tartrate
Dosage Form
CAPSULE
Strength
3 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
RIVASTIGMINE TARTRATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2016-03-25
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Rivastigmine Tartrate
Dosage Form
CAPSULE
Strength
4.5 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
RIVASTIGMINE TARTRATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2016-03-25
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Rivastigmine Tartrate
Dosage Form
CAPSULE
Strength
6 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
RIVASTIGMINE TARTRATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2016-03-25
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Memantine Hydrochloride
Dosage Form
TABLET, FILM COATED
Strength
5 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
MEMANTINE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2015-10-13
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Memantine Hydrochloride
Dosage Form
TABLET, FILM COATED
Strength
10 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
MEMANTINE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2015-10-13
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Olanzapine
Dosage Form
TABLET, ORALLY DISINTEGRATING
Strength
5 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
OLANZAPINE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2014-05-15
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Olanzapine
Dosage Form
TABLET, ORALLY DISINTEGRATING
Strength
10 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
OLANZAPINE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2014-05-15
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Olanzapine
Dosage Form
TABLET, ORALLY DISINTEGRATING
Strength
15 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
OLANZAPINE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2014-05-15
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Olanzapine
Dosage Form
TABLET, ORALLY DISINTEGRATING
Strength
20 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
OLANZAPINE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2014-05-15
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Aripiprazole
Dosage Form
TABLET
Strength
2 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ARIPIPRAZOLE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2015-10-08
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Aripiprazole
Dosage Form
TABLET
Strength
5 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ARIPIPRAZOLE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2015-10-08
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Aripiprazole
Dosage Form
TABLET
Strength
10 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ARIPIPRAZOLE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2015-10-08
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Aripiprazole
Dosage Form
TABLET
Strength
15 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ARIPIPRAZOLE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2015-10-08
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Aripiprazole
Dosage Form
TABLET
Strength
20 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ARIPIPRAZOLE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2015-10-08
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Aripiprazole
Dosage Form
TABLET
Strength
30 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ARIPIPRAZOLE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2015-10-08
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Repaglinide
Dosage Form
TABLET
Strength
0.5 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
REPAGLINIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2014-01-22
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Repaglinide
Dosage Form
TABLET
Strength
1 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
REPAGLINIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2014-01-22
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Repaglinide
Dosage Form
TABLET
Strength
2 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
REPAGLINIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2014-01-22
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Felodipine
Dosage Form
TABLET, FILM COATED, EXTENDED RELEASE
Strength
2.5 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
FELODIPINE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2013-01-17
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Felodipine
Dosage Form
TABLET, FILM COATED, EXTENDED RELEASE
Strength
5 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
FELODIPINE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2013-01-17
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Felodipine
Dosage Form
TABLET, FILM COATED, EXTENDED RELEASE
Strength
10 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
FELODIPINE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2013-01-17
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Alprazolam
Dosage Form
TABLET
Strength
0.25 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ALPRAZOLAM
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
CIV
Start Marketing Date
2015-07-31
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Alprazolam
Dosage Form
TABLET
Strength
0.5 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ALPRAZOLAM
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
CIV
Start Marketing Date
2015-07-31
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Alprazolam
Dosage Form
TABLET
Strength
1 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ALPRAZOLAM
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
CIV
Start Marketing Date
2015-07-31
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Alprazolam
Dosage Form
TABLET
Strength
2 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ALPRAZOLAM
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
CIV
Start Marketing Date
2015-07-31
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
RITONAVIR
Dosage Form
TABLET, FILM COATED
Strength
100 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
RITONAVIR
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2022-02-08
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Phenytoin Sodium
Dosage Form
CAPSULE
Strength
100 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
PHENYTOIN SODIUM
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2015-06-10
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
carisoprodol
Dosage Form
TABLET
Strength
250 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
CARISOPRODOL
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
CIV
Start Marketing Date
2016-11-08
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Venlafaxine Hydrochloride
Dosage Form
CAPSULE, EXTENDED RELEASE
Strength
150 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
VENLAFAXINE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2011-11-23
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Cefuroxime Axetil
Dosage Form
TABLET
Strength
125 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
CEFUROXIME AXETIL
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2006-03-29
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Cefuroxime Axetil
Dosage Form
TABLET
Strength
250 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
CEFUROXIME AXETIL
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2006-03-29
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Cefuroxime Axetil
Dosage Form
TABLET
Strength
500 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
CEFUROXIME AXETIL
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2006-03-29
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Ziprasidone Hydrochloride
Dosage Form
CAPSULE
Strength
20 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ZIPRASIDONE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2016-12-27
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Ziprasidone Hydrochloride
Dosage Form
CAPSULE
Strength
40 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ZIPRASIDONE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2016-12-27
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Ziprasidone Hydrochloride
Dosage Form
CAPSULE
Strength
60 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ZIPRASIDONE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2016-12-27
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Ziprasidone Hydrochloride
Dosage Form
CAPSULE
Strength
80 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ZIPRASIDONE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2016-12-27
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Raloxifene Hydrochloride
Dosage Form
TABLET, FILM COATED
Strength
60 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
RALOXIFENE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2015-08-28
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Atazanavir
Dosage Form
CAPSULE
Strength
100 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ATAZANAVIR SULFATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2018-06-25
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Atazanavir
Dosage Form
CAPSULE
Strength
150 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ATAZANAVIR SULFATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2018-06-25
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Atazanavir
Dosage Form
CAPSULE
Strength
200 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ATAZANAVIR SULFATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2018-06-25
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Atazanavir
Dosage Form
CAPSULE
Strength
300 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ATAZANAVIR SULFATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2018-06-25
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Rabeprazole Sodium
Dosage Form
TABLET, DELAYED RELEASE
Strength
20 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
RABEPRAZOLE SODIUM
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2017-02-17
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Olmesartan Medoxomil
Dosage Form
TABLET, FILM COATED
Strength
5 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
OLMESARTAN MEDOXOMIL
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2017-04-24
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Olmesartan Medoxomil
Dosage Form
TABLET, FILM COATED
Strength
20 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
OLMESARTAN MEDOXOMIL
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2017-04-24
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Olmesartan Medoxomil
Dosage Form
TABLET, FILM COATED
Strength
40 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
OLMESARTAN MEDOXOMIL
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2017-04-24
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
PREGABALIN
Dosage Form
CAPSULE
Strength
25 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
PREGABALIN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
CV
Start Marketing Date
2023-03-29
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
PREGABALIN
Dosage Form
CAPSULE
Strength
50 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
PREGABALIN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
CV
Start Marketing Date
2023-03-29
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
PREGABALIN
Dosage Form
CAPSULE
Strength
75 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
PREGABALIN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
CV
Start Marketing Date
2023-03-29
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
PREGABALIN
Dosage Form
CAPSULE
Strength
100 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
PREGABALIN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
CV
Start Marketing Date
2023-03-29
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
PREGABALIN
Dosage Form
CAPSULE
Strength
150 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
PREGABALIN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
CV
Start Marketing Date
2023-03-29
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
PREGABALIN
Dosage Form
CAPSULE
Strength
200 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
PREGABALIN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
CV
Start Marketing Date
2023-03-29
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
PREGABALIN
Dosage Form
CAPSULE
Strength
225 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
PREGABALIN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
CV
Start Marketing Date
2023-03-29
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
PREGABALIN
Dosage Form
CAPSULE
Strength
300 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
PREGABALIN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
CV
Start Marketing Date
2023-03-29
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Fenofibrate
Dosage Form
TABLET, COATED
Strength
48 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
FENOFIBRATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2016-05-05
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Fenofibrate
Dosage Form
TABLET, COATED
Strength
145 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
FENOFIBRATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2016-05-05
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Olmesartan Medoxomil and Hydrochlorothiazide
Dosage Form
TABLET, FILM COATED
Strength
12.5; 20 mg/1; mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2017-04-24
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Olmesartan Medoxomil and Hydrochlorothiazide
Dosage Form
TABLET, FILM COATED
Strength
12.5; 40 mg/1; mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2017-04-24
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Olmesartan Medoxomil and Hydrochlorothiazide
Dosage Form
TABLET, FILM COATED
Strength
25; 40 mg/1; mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2017-04-24
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Esomeprazole Magnesium
Dosage Form
CAPSULE, DELAYED RELEASE
Strength
20 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ESOMEPRAZOLE MAGNESIUM DIHYDRATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2016-04-21
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Esomeprazole Magnesium
Dosage Form
CAPSULE, DELAYED RELEASE
Strength
40 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ESOMEPRAZOLE MAGNESIUM DIHYDRATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2016-04-21
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Naproxen Sodium
Dosage Form
TABLET, FILM COATED
Strength
220 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
NAPROXEN SODIUM
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2016-03-18
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
CLOZAPINE
Dosage Form
TABLET
Strength
25 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
CLOZAPINE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2024-01-10
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
CLOZAPINE
Dosage Form
TABLET
Strength
50 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
CLOZAPINE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2024-01-10
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
CLOZAPINE
Dosage Form
TABLET
Strength
100 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
CLOZAPINE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2024-01-10
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
CLOZAPINE
Dosage Form
TABLET
Strength
200 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
CLOZAPINE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2024-01-10
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Tadalafil
Dosage Form
TABLET, FILM COATED
Strength
2.5 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
TADALAFIL
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2019-03-26
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Tadalafil
Dosage Form
TABLET, FILM COATED
Strength
5 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
TADALAFIL
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2019-03-26
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Tadalafil
Dosage Form
TABLET, FILM COATED
Strength
10 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
TADALAFIL
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2019-03-26
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Tadalafil
Dosage Form
TABLET, FILM COATED
Strength
20 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
TADALAFIL
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2019-03-26
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Famotidine
Dosage Form
TABLET, FILM COATED
Strength
20 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
FAMOTIDINE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2015-12-22
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Famotidine
Dosage Form
TABLET, FILM COATED
Strength
40 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
FAMOTIDINE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2015-12-22
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
nitrofurantoin (monohydrate/macrocrystals)
Dosage Form
CAPSULE
Strength
25; 75 mg/1; mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
NITROFURANTOIN; NITROFURANTOIN MONOHYDRATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2023-03-30
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
PARICALCITOL
Dosage Form
CAPSULE, LIQUID FILLED
Strength
1 ug/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
PARICALCITOL
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2021-08-23
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
PARICALCITOL
Dosage Form
CAPSULE, LIQUID FILLED
Strength
2 ug/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
PARICALCITOL
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2021-08-23
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
PARICALCITOL
Dosage Form
CAPSULE, LIQUID FILLED
Strength
4 ug/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
PARICALCITOL
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2021-08-23
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
LURASIDONE HYDROCHLORIDE
Dosage Form
TABLET
Strength
20 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
LURASIDONE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2023-03-10
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
LURASIDONE HYDROCHLORIDE
Dosage Form
TABLET
Strength
40 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
LURASIDONE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2023-03-10
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
LURASIDONE HYDROCHLORIDE
Dosage Form
TABLET
Strength
60 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
LURASIDONE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2023-03-10
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
LURASIDONE HYDROCHLORIDE
Dosage Form
TABLET
Strength
80 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
LURASIDONE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2023-03-10
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
LURASIDONE HYDROCHLORIDE
Dosage Form
TABLET
Strength
120 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
LURASIDONE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2023-03-10
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
ESZOPICLONE
Dosage Form
TABLET, FILM COATED
Strength
1 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ESZOPICLONE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
CIV
Start Marketing Date
2016-09-15
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
ESZOPICLONE
Dosage Form
TABLET, FILM COATED
Strength
2 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ESZOPICLONE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
CIV
Start Marketing Date
2016-09-15
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
ESZOPICLONE
Dosage Form
TABLET, FILM COATED
Strength
3 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ESZOPICLONE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
CIV
Start Marketing Date
2016-09-15
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Telmisartan and Hydrochlorothiazide
Dosage Form
TABLET
Strength
12.5; 40 mg/1; mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
HYDROCHLOROTHIAZIDE; TELMISARTAN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2016-12-15
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Telmisartan and Hydrochlorothiazide
Dosage Form
TABLET
Strength
12.5; 80 mg/1; mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
HYDROCHLOROTHIAZIDE; TELMISARTAN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2016-12-15
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Telmisartan and Hydrochlorothiazide
Dosage Form
TABLET
Strength
25; 80 mg/1; mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
HYDROCHLOROTHIAZIDE; TELMISARTAN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2016-12-15
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
BACLOFEN
Dosage Form
TABLET
Strength
5 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
BACLOFEN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2025-11-21
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Auropap 90F (Acetaminophen Directly Compressible Granules)
Dosage Form
GRANULE
Strength
50 kg/50kg
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ACETAMINOPHEN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2025-08-02
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Sertraline Hydrochloride
Dosage Form
TABLET, FILM COATED
Strength
25 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
SERTRALINE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2025-11-20
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Sertraline Hydrochloride
Dosage Form
TABLET, FILM COATED
Strength
50 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
SERTRALINE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2025-11-20
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Sertraline Hydrochloride
Dosage Form
TABLET, FILM COATED
Strength
100 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
SERTRALINE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2025-11-20
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Benazepril Hydrochloride
Dosage Form
TABLET, FILM COATED
Strength
10 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
BENAZEPRIL HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2026-01-13
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Benazepril Hydrochloride
Dosage Form
TABLET, FILM COATED
Strength
20 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
BENAZEPRIL HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2026-01-13
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Benazepril Hydrochloride
Dosage Form
TABLET, FILM COATED
Strength
40 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
BENAZEPRIL HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2026-01-13
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Fluoxetine
Dosage Form
TABLET, FILM COATED
Strength
10 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
FLUOXETINE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2026-01-15
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Fluoxetine
Dosage Form
TABLET, FILM COATED
Strength
20 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
FLUOXETINE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2026-01-15
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Fluoxetine
Dosage Form
TABLET, FILM COATED
Strength
60 mg/1
Labeler
Aurobindo Pharma Limited
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
FLUOXETINE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2026-01-15
End Marketing Date
-
Listing Record Certified Through
2027-12-31
NDC Type Breakdown
532 total- Drug for Further Processing
Official Source
NDC data is based on publicly available National Drug Code information from the U.S. Food and Drug Administration (FDA).
Visit FDA NDC DirectoryNDC Record Details Preview
Explore important National Drug Code information available in the records above.
NDC
59651-001
Nonproprietary Name
Omeprazole
Labeler
Aurobindo Pharma Limited
Dosage Form
CAPSULE, DELAYED RELEASE
FDA NDC Data
National Drug Code information
Regular Updates
Data maintained from official sources
Structured Database
Searchable pharmaceutical data
Reliable Data
Organized NDC records
Create a New Buying Request
Fields marked with * are mandatory.